摘要
目的:探讨尖吻蝮蛇血凝酶联合垂体后叶素治疗经皮肾镜碎石取石术后患者出血的临床疗效。方法:回顾性选取2018年6月—2020年12月本院泌尿外科接受经皮肾镜碎石取石术治疗的90例患者,按不同治疗方法分为对照组和研究组,各45例。两组患者均给予尖吻蝮蛇血凝酶注射剂注入氯化钠注射液100 ml稀释后静脉滴注,2 U/次,1次/d,连续用药3 d。研究组在对照组基础上联用垂体后叶素注射剂,将垂体后叶素注射剂注入5%葡萄糖注射液100 ml稀释后静脉滴注,24 U/次,1次/d,连续用药3 d。观察两组患者在术后的第3日、第5日、第7日的出血情况,住院时间和止血时间,肾功能指标的改善及不良反应发生情况。结果:研究组患者在术后的第3日、第5日、第7日的出血量均明显少于对照组(P<0.05);其住院时间和止血时间均明显少于对照组(P<0.05);两组患者治疗前后肾功能的主要指标(血清尿素氮、血清肌酐和尿微量白蛋白)比较均有改善(P<0.05),治疗后研究组患者肾功能指标的改善明显优于对照组(P<0.05);研究组患者的不良反应发生率为28.89%,但多数可耐受,对照组患者的不良反应发生率8.89%,两组比较有统计学意义(P<0.05)。结论:尖吻蝮蛇血凝酶联合垂体后叶素治疗经皮肾镜碎石取石术后出血的临床疗效肯定,可明显减低术后的出血量,减少患者的住院时间和止血时间,且有助于术后肾功能的保护,可在临床应用。
Objective:To investigate the clinical effect of haemocoagulase agkistrodon combined with pituitrin in the treatment of bleeding after percutaneous nephroscopy.Methods:A total of 90 patients who received percutaneous nephrolithotomy in the department of urology in our hospital from June 2018 to December 2020 were retrospectively selected and divided into the control group and the study group according to different treatment methods,with 45 patients in each group.Both groups were intravenously given haemocoagulase agkistrodon injection(2 U/time,diluted into 100 ml normal saline,once a day)for three successive days.Based on the control group,the study group was intravenously given pituitrin injection(24 U/time,diluted into 100 ml 5%glucose injection,once a day)for three successive days.The bleeding situation,hospital stay and hemostasis time,the occurrence of adverse reactions,and renal function indexes of patients in both groups were observed on the third,fifth,and seventh day after surgery.Results:The amount of bleeding in the study group was significantly less than that in the control group on the third,fifth,and seventh postoperative days(P<0.05).The length of hospital stay and hemostasis time were significantly shorter than those in the control group(P<0.05).The main indexes of renal function(BUN,SCr,and ALB)in the study group were significantly better than those in the control group(P<0.05).However,the incidence of adverse reactions was 28.89%in the study group and 8.89%in the control group,which was significantly higher than that in the control group(P<0.05).Conclu sion:haemocoagulase agkistrodon combined with pituitrin has significant clinical efficacy in treating postoperative bleeding after percutaneous nephroscopy,which can significantly reduce the amount of postoperative bleeding,reduce the length of hospital stay and hemostasis time of patients,and contribute to the protection of postoperative renal function.This scheme is safe and feasible,and worthy of clinical reference.
作者
蔡科科
Cai Keke(Tianjin Nankai Hospital,Tianjin 300102)
出处
《天津药学》
2021年第6期29-32,共4页
Tianjin Pharmacy
